PARSIPPANY, N.J., Sept. 12, 2016 /PRNewswire/ -- Interpace
Diagnostics Group (NASDAQ: IDXG), a company that provides
clinically useful molecular diagnostic tests and pathology services
for evaluating risk of cancer by leveraging the latest technology
in personalized medicine for better patient diagnosis and
management, reported today that two short call abstracts submitted
by the Company have been accepted for poster presentations at the
upcoming 86th Annual Meeting of the American Thyroid Association
(ATA) in Denver, Colorado on
September 15th, 2016. The
studies being presented demonstrate the robust nature of ThyGenX
and ThyraMir's performance across a wide array of specimen
types.
The first of the two posters entitled "Molecular Analysis of
Thyroid Malignancy Using Cytology Smears by Combined THYGENX™ and
THYRAMIR™ testing: A Prospective Study" highlights the clinical
performance of the combined ThyGenX + ThyraMIR tests when carried
out on Fine Needle Aspirate (FNA) material smeared on cytology
slides.
The second poster entitled "The Majority of Non-Diagnostic
(Insufficient) Thyroid Nodule Cytology Samples Can Effectively
Undergo Molecular (Combined Mutational and MicroRNA Classifier)
Analysis Using a Needle Aspiration Approach" demonstrates that
Interpace's scientists were able to perform molecular analysis in
cases where cytology results were insufficient.
"Both of these posters being accepted by an organization as
influential as the ATA indicates that the innovative work we do is
critically important and ultimately affects both the cost and the
quality of care provided to patients with suspected thyroid cancer"
said Jack Stover, President and CEO
of Interpace.
About Thyroid Nodules, ThyGenX and ThyraMIR
testing
According to the American Thyroid Association,
approximately 15% to 30% of the 525,000 thyroid fine needle
aspirations (FNAs) performed on an annual basis in the U.S. are
indeterminate for malignancy based on standard cytological
evaluation, and thus are candidates for ThyGenX and
ThyraMIR.ThyGenX and ThyraMIR reflex testing yields high predictive
value in determining the presence and absence of cancer in thyroid
nodules. The combination of both tests can improve risk
stratification and surgical decision-making when standard
cytopathology does not provide a clear diagnosis for the presence
of cancer. ThyGenX utilizes state-of-the-art next-generation
sequencing (NGS) to identify more than 100 genetic alterations
associated with papillary and follicular thyroid carcinomas, the
two most common forms of thyroid cancer. ThyraMIR is the first
microRNA gene expression classifier. MicroRNAs are small,
non-coding RNAs that bind to messenger RNA and regulate expression
of genes involved in human cancers, including every subtype of
thyroid cancer. ThyraMIR measures the expression of 10
microRNAs. Both ThyGenX and ThyraMIR are covered by both
Medicare and Commercial insurers.
About Interpace Diagnostics Group, Inc.
Interpace
Diagnostics provides clinically useful molecular diagnostic tests
and pathology services for evaluating risk of cancer by leveraging
the latest technology in personalized medicine for better patient
diagnosis and management. The Company currently has three
commercialized molecular tests: PancraGen® for the evaluation of
pancreatic cysts and assessment of risk of concomitant or
subsequent cancer; ThyGenX®, for the diagnosis of thyroid
cancer from thyroid nodules utilizing a next generation sequencing
assay; and ThyraMIR®, for the diagnosis of thyroid cancer from
thyroid nodules utilizing a proprietary gene expression assay.
Interpace Diagnostics mission is to provide personalized medicine
through molecular diagnostics and innovation to advance patient
care based on rigorous science.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995, relating to our future financial and operating
performance. The company has attempted to identify forward looking
statements by terminology including "believes," "estimates,"
"anticipates," "expects," "plans," "projects," "intends,"
"potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes to identify these forward-looking
statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond company's control. These statements also involve known and
unknown risks, uncertainties and other factors that may cause
company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to, our ability to adequately finance the business, our
ability to restructure our debt and other obligations, the market's
acceptance of our molecular diagnostic tests, our ability to secure
additional business and generate higher profit margins through
sales of our molecular diagnostic tests, in-licensing or other
means, projections of future revenues, growth, gross profit and
anticipated internal rate of return on investments. Additionally,
all forward-looking statements are subject to the risk factors
detailed from time to time in the company's periodic filings with
the Securities and Exchange Commission (SEC), including without
limitation, the Annual Report on Form 10-K filed with the SEC on
March 30, 2016, as amended on
April 29, 2016 and June 14, 2016. Because of these and other
risks, uncertainties and assumptions, undue reliance should not be
placed on these forward-looking statements. In addition, these
statements speak only as of the date of this press release and,
except as may be required by law, the Company undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
CONTACTS:
Interpace Diagnostics
Investor Relations:
Dave Schemelia
EVC Group, Inc.
(646)201-5431
dave@evcgroup.com
Doug Sherk
EVC Group, Inc.
(646)445-4800
dsherk@evcgroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-invited-to-present-data-at-upcoming-american-thyroid-association-ata-annual-meeting-300326242.html
SOURCE Interpace Diagnostics Group